Patent · US Active

Compositions and methods of use for antibodies of c-Met

US8101727B2 · kind B2 · utility

25Cited by

5References

31Claims

0Family size

Assignee

Novartis AG · CH

Inventors

David Stover · Sylvia Park, US
Josef Prassler · Germering, DE
Catrin Berger · Germering, DE
Bodo BROCKS · Gilching, DE

Key dates

Filing date	Mar 29, 2007
Grant date	Jan 24, 2012
Priority date	—
Expiry date	Jan 25, 2028

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S435/81
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Antibodies and fragments that bind to the protein target c-Met, particularly to epitopes located in the c-Met extracellular domain, are provided, as are methods of use of the antibodies and kits, for treating an unwanted cell, in particular, a cell associated with a c-Met-related condition such as a cancer, a metastasis, or an inflammatory condition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.